262 related articles for article (PubMed ID: 34651192)
1. Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting.
Deschanvres C; Reynes J; Lamaury I; Rey D; Palich R; Bani-Sadr F; Robineau O; Duvivier C; Hocqueloux L; Cuzin L; Joly V; Raffi F; Cabie A; Allavena C;
J Antimicrob Chemother; 2021 Dec; 77(1):196-204. PubMed ID: 34651192
[TBL] [Abstract][Full Text] [Related]
2. Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study.
Gagliardini R; Baccini M; Modica S; Montagnani F; Zanelli G; Borghetti A; Dreassi E; Lombardi F; Pecorari M; Borghi V; Callegaro A; Micheli V; Lodi MA; Rossetti B; Zazzi M;
J Glob Antimicrob Resist; 2022 Mar; 28():274-281. PubMed ID: 35092828
[TBL] [Abstract][Full Text] [Related]
3. Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients.
Galizzi N; Poli A; Galli L; Muccini C; Mastrangelo A; Dell'Acqua R; Maillard M; Bossolasco S; Cinque P; Lazzarin A; Castagna A; Gianotti N
Int J Antimicrob Agents; 2020 Mar; 55(3):105893. PubMed ID: 31926287
[TBL] [Abstract][Full Text] [Related]
4. Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients.
Gianotti N; Poli A; Nozza S; Galli L; Galizzi N; Ripa M; Merli M; Carbone A; Spagnuolo V; Lazzarin A; Castagna A
BMC Infect Dis; 2017 Nov; 17(1):723. PubMed ID: 29145807
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study.
Asare K; Sookrajh Y; van der Molen J; Khubone T; Lewis L; Lessells RJ; Naidoo K; Sosibo P; van Heerden R; Garrett N; Dorward J
Lancet Glob Health; 2024 Feb; 12(2):e282-e291. PubMed ID: 38142692
[TBL] [Abstract][Full Text] [Related]
6. Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen.
Keene CM; Griesel R; Zhao Y; Gcwabe Z; Sayed K; Hill A; Cassidy T; Ngwenya O; Jackson A; van Zyl G; Schutz C; Goliath R; Flowers T; Goemaere E; Wiesner L; Simmons B; Maartens G; Meintjes G
AIDS; 2021 Jul; 35(9):1423-1432. PubMed ID: 33973876
[TBL] [Abstract][Full Text] [Related]
7. Analysing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicentre cohort of virologically suppressed PLWHIV.
Ciccullo A; Baldin G; Borghi V; Cossu MV; Giacomelli A; Lagi F; Farinacci D; Iannone V; Passerotto RA; Capetti A; Sterrantino G; Mussini C; Antinori S; Di Giambenedetto S
J Antimicrob Chemother; 2022 Dec; 78(1):117-121. PubMed ID: 36272137
[TBL] [Abstract][Full Text] [Related]
8. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
[TBL] [Abstract][Full Text] [Related]
9. Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.
Moyle G; Assoumou L; de Castro N; Post FA; Curran A; Rusconi S; De Wit S; Stephan C; Raffi F; Johnson M; Masia M; Vera J; Jones B; Grove R; Fletcher C; Duffy A; Morris K; Pozniak A;
Lancet HIV; 2024 Mar; 11(3):e156-e166. PubMed ID: 38417976
[TBL] [Abstract][Full Text] [Related]
10. Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety.
Cento V; Perno CF
J Glob Antimicrob Resist; 2020 Mar; 20():228-237. PubMed ID: 31446092
[TBL] [Abstract][Full Text] [Related]
11. Virological outcomes with dolutegravir plus either lamivudine or two NRTIs as switch strategies: a multi-cohort study.
Borghetti A; Alkhatib M; Dusina A; Duca L; Borghi V; Zazzi M; Di Giambenedetto S
J Antimicrob Chemother; 2022 Feb; 77(3):740-746. PubMed ID: 34849981
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
Borghetti A; Lombardi F; Gagliardini R; Baldin G; Ciccullo A; Moschese D; Emiliozzi A; Belmonti S; Lamonica S; Montagnani F; Visconti E; De Luca A; Di Giambenedetto S
BMC Infect Dis; 2019 Jan; 19(1):59. PubMed ID: 30654739
[TBL] [Abstract][Full Text] [Related]
13. Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy.
Gagliardini R; Gianotti N; Maggiolo F; Cozzi-Lepri A; Antinori A; Nozza S; Lapadula G; De Luca A; Mussini C; Gori A; Saracino A; Andreoni M; Monforte AD;
Int J Antimicrob Agents; 2021 Oct; 58(4):106406. PubMed ID: 34293454
[TBL] [Abstract][Full Text] [Related]
14. Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding.
Ciccullo A; Borghi V; Giacomelli A; Cossu MV; Sterrantino G; Latini A; Giacometti A; De Vito A; Gennari W; Madeddu G; Capetti A; d'Ettorre G; Mussini C; Rusconi S; Di Giambenedetto S; Baldin G
J Acquir Immune Defic Syndr; 2021 Nov; 88(3):234-237. PubMed ID: 34446677
[TBL] [Abstract][Full Text] [Related]
15. Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens.
Chen GJ; Sun HY; Chen LY; Hsieh SM; Sheng WH; Liu WD; Chuang YC; Huang YS; Lin KY; Wu PY; Chang HY; Luo YZ; Su YC; Liu WC; Chang SF; Chang SY; Hung CC
Int J Antimicrob Agents; 2022 Sep; 60(3):106631. PubMed ID: 35787920
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial.
Rojas J; de Lazzari E; Negredo E; Domingo P; Tiraboschi J; Ribera E; Abdulghani N; Puig J; Mateo MG; Podzamczer D; Gutierrez MM; Paredes R; Clotet B; Gatell JM; Blanco JL; Martínez E;
Lancet HIV; 2021 Aug; 8(8):e463-e473. PubMed ID: 34358497
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort.
Fabbiani M; Rossetti B; Ciccullo A; Oreni L; Lagi F; Celani L; Colafigli M; De Vito A; Mazzitelli M; Dusina A; Durante M; Montagnani F; Rusconi S; Capetti A; Sterrantino G; D'Ettorre G; Di Giambenedetto S;
HIV Med; 2021 Oct; 22(9):843-853. PubMed ID: 34318591
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination.
Lambert-Niclot S; Allavena C; Grude M; Flandre P; Sayon S; Andre E; Wirden M; Rodallec A; Jovelin T; Katlama C; Calvez V; Raffi F; Marcelin AG
J Antimicrob Chemother; 2016 Aug; 71(8):2248-51. PubMed ID: 27231280
[TBL] [Abstract][Full Text] [Related]
19. M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients.
Jary A; Marcelin AG; Charpentier C; Wirden M; Lê MP; Peytavin G; Descamps D; Calvez V
J Antimicrob Chemother; 2020 May; 75(5):1290-1293. PubMed ID: 32065630
[TBL] [Abstract][Full Text] [Related]
20. Dolutegravir in the long term in children and adolescents: frequent virological failure but rare acquired genotypic resistance.
Frange P; Blanche S; Veber F; Avettand-Fenoel V
HIV Med; 2021 Nov; 22(10):958-964. PubMed ID: 34369051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
